Stemline Therapeutics (STML) Files $50M IPO
Tweet
Share
E-mailGet Alerts STML Hot Sheet
Join SI Premium – FREE
In a Form S-1 late Monday, Stemline Therapeutics (Nasdaq: STML) registered a $50 million initial public offering. The company plans to list on the NASDAQ under the symbol "STML."
The offering is being made through Oppenheimer and JMP Securities.
Stemline is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.
The offering is being made through Oppenheimer and JMP Securities.
Stemline is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Karman Line Acquisition prices $200M IPO on Nasdaq
- Londian Wason prices IPO at $22 per ADS, raising $94.3 million
- Thunder Bridge Capital Partners V prices $261M IPO on Nasdaq
Create E-mail Alert Related Categories
IPOsRelated Entities
JMP Securities, S1Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
